Proximity spinal disease is a chronic inflammation disease, which mainly infringes on the hips, spinal fractures, soft tissues by the spinal column and the outer joints, which seriously affects the quality of life of patients. Traditional treatments include inflammation drugs, improved rheumatism, etc., but some patients are less effective or resistant to the side effects. The emergence of biological agents has brought new breakthroughs in the treatment of direct spinal disease.
Biological agents are single cloned antibodies or integrated proteins produced through genetic engineering, capable of specific target effects on cytogens or cell surface molecules that are closely related to the mechanism for the disease of a direct spinal column, thus blocking critical elements of inflammation response. The biological agents currently used in clinical practice include, inter alia, tumour necrosis inhibitor (TNFi), white cellulose-17 inhibitor (IL-17i).
A number of clinical studies have shown that biological agents have a significant therapeutic effect in the treatment of direct spinal disease. Biological agents are often able to function in a short period of time to alleviate pain, rigidity and symptoms in patients. Compared to traditional medicines, patients treated with biological agents have experienced a marked reduction in their morning rigidity within 1-2 weeks of treatment, a significant decrease in the vas scale of the back pain visual simulation (VAS) and an improvement in the level of joint activity, which has led to an increase in their daily life capacity and better access to clothing, washing and walking activities.
Biological agents show unique advantages in controlling the progress of diseases. The long-term application of biological agents can inhibit structural damage to the spinal and gill joints and reduce the risk of new bone formation and joint integration. The study found that the pace of spinal imaging progress for patients receiving TNFi treatment has slowed significantly, and that some patients, even after several years of continuous treatment, have made almost no significant progress in their spinal pathologies, which is crucial for preventing disability.
Biological agents also improve the overall quality of life and physical functioning of patients. After being treated with biological agents, patients not only reduced their physical pain but their psychological state was adjusted. The effective control of the disease has enabled patients to become more involved in social activities, to resume work or to engage in physical exercise, thus enhancing self-confidence and life satisfaction.
However, the use of biological agents is not without risk. Infection is one of its most significant adverse effects, especially the increased risk of infection of the tuberculosis streptococcus. Therefore, before biological agents are used, a full-scale tuberculosis screening of patients, including chest X-lines, tuberculosis fungus test (PPD) or gamma-interferobic release test (IGRA) etc., must be carried out and the patient ‘ s symptoms of infection closely monitored during treatment. In addition, biological agents can lead to injections, allergies, etc., but the overall incidence is relatively low.
Biological agents have produced significant clinical effects for patients with direct spina syndrome and play an important role in mitigating symptoms, controlling the progress of the disease and improving the quality of life. However, in the process of use, the efficacy and safety of treatment needs to be fully weighed, adaptive certificates are rigorously developed, adverse reactions are closely monitored, and biological agents are better served by individualized treatment programmes for people with high straight spinal diseases. As medical research continues, it is believed that there will be more safer and more effective biological agents and treatment strategies in the future, which will bring new light to the treatment of direct spina.
